Article 3 min read

New Jersey’s 2026 NOL Program: Turn Unused Tax Attributes Into Working Capital

Ray Jabagjorian
Ray Jabagjorian

The New Jersey Economic Development Authority (NJEDA) will open the application window for the 2026 Technology Business Tax Certificate Transfer Program (the “NOL Program”) on May 1, 2026, with submissions due no later than June 30, 2026. For emerging and growth stage technology and biotechnology companies, this long standing incentive continues to be one of the most valuable sources for companies looking to monetize unused tax attributes.

The NOL Program allows qualified companies to sell a portion of their net operating losses (NOLs) and unused R&D tax credits to unrelated, profitable New Jersey corporations. This program enables businesses that are often pre revenue or pre profit to convert tax assets into immediate working capital to support R&D, hiring, and expansion.

With more than $75 million available annually, including $15 million set aside for companies located in Innovation Zones, Opportunity Zones, or certified as minority or woman owned, the program remains a cornerstone of New Jersey’s strategy to strengthen its innovation economy.

life-sciences-tax-credit-nol-nj-program-fifty

Key Benefits

Approved applicants may sell their NOLs and R&D tax credits for at least 80% of their value and are eligible to receive up to $20 million in lifetime benefits. This funding can be used for:

  • Working capital
  • Research and development activities
  • Equipment purchases
  • Facility build out or expansion
  • Other eligible operational expenditures

Eligibility Criteria

To participate in the NOL Program, companies must meet several statutory and administrative requirements. Key criteria include:

  • Industry Requirement: The business must be a technology or biotechnology company whose primary activity involves a scientific process, product, or service.
  • Intellectual Property: Applicants must own, have filed for, or be licensed to use protected proprietary intellectual property (patents or registered copyrights).
  • Financial Position: The company must have no positive net operating income in either of its two most recent full year GAAP financial statements. This requirement also applies to parent companies and consolidated groups.
  • Employee Thresholds:
    • 1–224 total U.S. employees (including subsidiaries)
    • Minimum New Jersey full time employees based on company age:
      • 1 employee if <3 years old
      • 5 employees if 3–5 years old
      • 10 employees if >5 years old
  • Financial Statements: The two most recent full year financial statements must be compiled, reviewed, or audited by an independent CPA firm.
  • Ongoing Compliance: Eligibility must be maintained both at application and at benefit closing.

Fees

Companies should plan for the following non-refundable program fees:

  • Application Fee: $1,000
  • Approval Fee: 1% of the tax benefit award (capped at $20,000). The application fee is credited toward this amount.

Application Timeline and Process

The 2026 application cycle will run as follows:

  • Opening Date: May 1, 2026
  • Submission Deadline: June 30, 2026

Takeaway

For New Jersey based technology and biotechnology companies, the NOL Program remains a powerful tool for transforming tax attributes into immediate, non dilutive capital. With the 2026 application window opening on May 1, now is the time for companies to evaluate eligibility, prepare financial documentation, and consider how NOL monetization can support their growth and innovation plans.

Withum plus signs

Have Questions or Need Guidance?

For more information on this topic, please contact a member of our team.

Contact Us

Related Insights

Read more
DNA helix with dollar sign representing the value of life sciences.
Life Sciences Valuations in Tight Capital Markets: When Uncertainty Creates Value

In today’s constrained capital markets, uncertainty has become a primary driver of value in the global life sciences sector. Biotechnology, pharmaceutical, and medical device companies, particularly those operating in innovation hubs such as the United States, Europe, and Asia-Pacific, are increasingly valued on future milestones rather than historical performance. Shifting capital dynamics are reshaping business…

Read more
women in life sciences
Women Leading Life Sciences: A Withum Spotlight Series

Women’s History Month is a time to recognize the impact, leadership and lasting contributions of women across various industries. For those in life sciences, those contributions are shaping innovation, improving patient outcomes and driving meaningful progress. At Withum, we’re proud to work alongside and learn from women who are advancing this dynamic field. In honor…

Read more
2025 MLSC Tax Incentives
2026 MLSC Tax Incentive Program: Key Considerations for Massachusetts Life Sciences Companies

The Massachusetts Life Sciences Center (MLSC) has opened the application window for the 2026 Tax Incentive Program, making up to $40 million in tax incentives available to eligible life sciences companies of any size operating in the Commonwealth. The program is intended to support companies engaging in research and development, commercialization, and manufacturing that are…